

Comparison of outcomes between endoscopic and microscopic transsphenoidal surgery for the treatment of pituitary adenoma: a meta-analysis

Xiaolin Chen, Wei Huang, Hongjuan Li, Yan Huan, Guoying Mai, Luming Chen, Hongqiang Huang, Haoxiang Xu

The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

Contributions: (I) Conception and design: X Chen; (II) Administrative support: W Huang, H Li; (III) Provision of study materials or patients: Y Huan, G Mai, L Chen; (IV) Collection and assembly of data: X Chen, W Huang, H Li; (V) Data analysis and interpretation: X Chen, W Huang, H Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Hongqiang Huang. The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China. Email: hhqiang1888@163.com.

Background: Pituitary tumors are among the most common intracranial tumors. Surgical resection is the most effective treatment for patients with pituitary tumors. Microscopic transsphenoidal surgery has become the first-choice surgical approach to treating this malignancy, although it has certain limitations. Neuroendoscopy has also been widely used for pituitary tumor surgery in recent years. This study aimed to compare the efficacy and safety of these two surgical options for the treatment of pituitary tumors.

Methods: We conducted a literature search of the PubMed, Embase, Cochrane Controlled Center Register of Controlled Trials (CENTRAL), Web of Science database, Google Scholar, and Baidu Scholar. Relevant articles published up to September 25, 2020 were retrieved and then meta-analyzed using RevMan software 5.1.

Results: A total of 29 case-control studies involving 7,774 patients were included in the meta-analysis. There was no significant difference in gross tumor removal (GTR) (RR =1.11, 95% CI: 0.97–1.26, P=0.12) or hormone excess secretion (HES) remission (RR =1.08, 95% CI: 0.97–1.21, P=0.16) between the two groups. Endoscopic transsphenoidal surgery was associated with a lower incidence of diabetes insipidus (DI) than was microscopic transsphenoidal surgery (RR =0.76, 95% CI: 0.60–0.97, P=0.03).

Conclusions: Endoscopic transsphenoidal surgery does not significantly improve GTR or HES remission, but it can reduce the incidence of DI without increasing the rates of other complications.

Keywords: Pituitary tumor, endoscopy, meta-analysis

Submitted Oct 19, 2020. Accepted for publication Dec 08, 2020. doi: 10.21037/gs-20-851 View this article at: http://dx.doi.org/10.21037/gs-20-851

Introduction

Pituitary tumors comprise 10% of intracranial tumors, placing them among the most common malignancies of the brain (1). The main clinical manifestations of pituitary tumor are hormone over-secretion and tumor compression. Treatment methods include drug therapy, radiation therapy, and surgery, with surgical resection being the most effective treatment. However, the pituitary tumor is located deep in the pituitary fossa, adjacent to important structures such as the hypothalamus, cavernous sinus, and internal carotid artery, which limits the visual field and makes tumor removal using traditional surgical methods risky. Transsphenoidal resection was first proposed as a treatment for pituitary adenomas by Schloffer in January 1907 (2). Since 1960, transsphenoidal surgery under a microscope has become the first-choice approach for patients who require

intrasellar surgery. The success rate of surgery is high, while the risk and incidence of complications are low. However, surgery still has certain limitations, especially the poor visibility.

With the development of endoscopic technology, surgery has entered a new era. In 1992, Jankowski was the first to apply endoscopy in pituitary tumor surgery (3). The lens angle of the neuroendoscope can be changed to provide a wider operative field of view, facilitating better observation. The anatomic area exposed by the endoscope is anterior to the optic chiasm, lateral to the lateral wall of the cavernous sinus, and posterior to the end of the basilar artery. In 2007, Laufer *et al.* concluded that endoscopic surgery is safe for transsphenoidal enlargement surgery (4).

In recent years, a number of studies have compared the efficacy and safety of the neuroendoscopic and microscopic transsphenoidal approaches in the treatment of pituitary tumor, but the results have been inconsistent. In order to determine the effectiveness of the neuroendoscopic transsphenoidal approach in pituitary tumor treatment, a meta-analysis of all available studies published to date was conducted to comprehensively evaluate the efficacy and safety of neuro-endoscopic transsphenoidal approach in patients with pituitary tumors. We present the following article in accordance with the PRISMA reporting checklist (available at http://dx.doi.org/10.21037/gs-20-851).

Methods

Literature search

We conducted a literature search of PubMed, Embase, Cochrane Controlled Center Register of Controlled Trials (CENTRAL), Web of Science database, Google Scholar, and Baidu Scholar. The reference lists of retrieved literature were also searched to identify any relevant articles. The databases were searched from inception to August 25, 2020, and there were no language restrictions. The search strategy was formulated with reference to the Cochrane Handbook. English keywords used for searches included "pituitary tumor", "Cushing syndrome", "Cushing disease", "Acromegaly", "pituitary adenomas", "microscopic*", "endoscopic*", "transsphenoidal*".

Inclusion and exclusion criteria

The inclusion criteria were: (I) publicly published casecontrol studies; (II) study subjects were patients with pituitary tumors aged >18 years; (III) the experimental group was treated with neuro-endoscopic transsphenoidal pituitary tumor resection, and the control group was treated with microscopic transsphenoidal pituitary tumor resection; (IV) the study outcome indicators included: gross tumor removal (GTR); hormone excess secretion (HES) remission; the incidence of adverse reactions, including cerebrospinal fluid (CSF) leakage, diabetes insipidus (DI), epistaxis, hypopituitarism, meningitis, overall complications, visual improvement, and vision loss. Articles that did not meet the inclusion criteria, articles that did not include the main outcome indicators, or without a response from the author, or published repeatedly were excluded.

Information and data extraction

The full texts of the retrieved studies were read to obtain the general study characteristics, as well as the inclusion criteria, basic information of the study subjects, intervention measures, follow-up time, and main results. For data that could not be obtained from the published studies, we contacted the authors via email. The studies were read and the data were extracted by two authors independently. Any inconsistency or disagreement that arose regarding the data was resolved through discussion. If after a discussion, a consensus still had not been reached, a third reviewer was consulted for their opinion.

Literature quality evaluation

Two researchers evaluated the included literature according to the Newcastle-Ottawa Scale (NOS) (5). This quality evaluation standard includes seven items across the following three domains: (I) selection of the study population: whether the case determination was appropriate; representativeness of the cases; selection of the controls, and determination of the controls; (II) comparability between groups: consideration of the comparability of cases and controls in the study design and statistical analysis; and (III) measurement of exposure factors: determination of the exposure factors; whether the same method was used to determine the exposure factors of the cases and controls; and the non-response rate.

Statistical methods

The meta-analysis was performed using RevMan5.1

2164

software (Cochrane Center, London, England), available from Cochrane. Heterogeneity among the studies was analyzed using the χ^2 test and I² test. If the homogeneity between studies was good (I² <50%, P>0.1), the fixed-effects model was adopted; otherwise, the random-effects model was used. When clinical data could not be meta-analyzed, descriptive analysis was carried out.

Results

Literature search results

The initial search retrieved 577 articles, and after the elimination of duplicates with EndNote software, 443 articles remained. After the titles, abstracts, and full texts of these articles had been read, 29 articles that met the inclusion criteria were finally included in the meta-analysis and are shown in *Table 1*. The literature screening flowchart is displayed in *Figure 1*.

General characteristics of the included articles

A total of 29 studies, involving 4,557 patients, were included in this meta-analysis. All of the studies were designed as case-control studies and were published between 1999 and 2020. Patient populations mainly comprised Europeans, North Americans, and South Americans. Major countries involved in these studies included the United States, the United Kingdom, India, Canada, Italy, Finland, Iran, Norway, Belgium, North Korea, France, and China. The general information of the included articles is shown in *Table 1*.

Quality evaluation

The results of the quality evaluation of the included articles are shown in *Table 2*.

Meta-analysis results

Gross tumor removal

Fourteen studies reported the total tumor resection rates of endoscopic transsphenoidal resection and microscopic transsphenoidal resection in patients with pituitary tumors. The results showed that there was no significant difference in the tumor total resection rate between the endoscopic surgery group and the microscopic surgery group (RR =1.11, 95% CI: 0.97-1.26, P=0.12, Figure 2).

Hormone excess secretion remission

Ten studies reported the remission rates of hormone oversecretion in patients with pituitary tumors who underwent endoscopic or microscopic transphenoidal resection. The results showed that there was no significant difference in the remission rate of hormone over-secretion between the endoscopic surgery group and the microscopic surgery group (RR =1.08, 95% CI: 0.97–1.21, P=0.16, *Figure 3*).

Overall complications

Nine studies reported the total complication rates of endoscopic transsphenoidal resection and microscopic transsphenoidal resection in patients with pituitary tumors. The results revealed no significant difference in the overall complication rate between the endoscopic surgery group and the microscopic surgery group (RR =0.82, 95% CI: 0.54–1.23, P=0.34, *Figure 4*).

Cerebrospinal fluid leakage

Twenty-five studies reported the incidence of postoperative CSF leakage in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. The results showed no significant difference in the incidence of CSF leakage between the endoscopic surgery group and the microscopic surgery group (RR =1.06, 95% CI: 0.88–1.28, P=0.51, *Figure 5*).

Diabetes insipidus

Twenty studies reported the incidence of postoperative DI in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. The results revealed the incidence of DI in the endoscopic surgery group to be significantly lower than that in the microscopic surgery group, and the difference was statistically significant (RR =0.76, 95% CI: 0.60–0.97, P=0.03, *Figure 6*).

Epistaxis

Five studies reported the incidence of postoperative epistaxis in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. The results showed no significant difference in the incidence of epistaxis between the endoscopic surgery

		Ċ	Sample size		Ċ	Ý	Age	Ň	Sex
study	stuay perioa	stuay aesign	(end/mic)	Country	Ulsease	Endoscopic	Microscopic	Endoscopic	Microscopic
Bora SK 2020 (6)	2009.1-2009.6	Retrospective	55/47	India	Cushing disease	28 (5	28 (9–55)		
Pablo A 2019 (7)	2011.3–2014.12	Retrospective	140/259	Argentina	Pituitary adenomas	48.5 (18–85)	51(17–90)	61/79	109/150
Agam MS 2018 (8)	1992.11–2017.3	Retrospective	170/983	NSA	Pituitary adenomas	53.3 (13.6)	49.1 (16.6)		
Akbari H 2018 (9)	2012–2014	Retrospective	16/19	Iran	Pituitary adenomas	39.43±15.2	43.06±11.29	19,	19/16
Wang AC 2018 (10)	2003.1–2012.8	Retrospective	117/37	NSA	Pituitary adenomas	50	52	54/63	10/27
Eseonu CI 2017 (11)	2005.5–2005.8	Retrospective	275/109	NSA	Pituitary adenomas	49.0±16.2	48.8±15.8	163,	163/221
Levi V 2017 (12)	2004–2012	Retrospective	140/81	Italy	Pituitary adenomas	58.5	52	130	130/91
Fathalla H 2015 (13)	2000–2013	Retrospective	42/23	Canada	Acromegaly	43.2	42.1	21/21	7/16
Karppinen A 2015 (14)		Retrospective	41/144	Finland	Nonfunctioning pituitary adenomas	58.5±16	58.4±13	118	118/67
Lenzi J 2015 (15)	1996–2006	Retrospective	22/15	Italy	Acromegaly				
Dallapiazza R 2014 (16)	2010.6–2013.1	Retrospective	56/43	NSA	Nonfunctioning pituitary adenomas	56.2±12.8	56.7±16.9	51	51/48
Halvorsen H 2014 (17)	2020.9–2011.2	Retrospective	238/268	Norway	Pituitary adenomas			291,	291/215
Sarkar S 2014 (18)	2005.1–2013.4	Retrospective	66/47	India	Acromegaly	37.6±10.8	38.7±12.2	30/36	26/21
Alahmadi H 2013 (19)	2000-2010	Retrospective	17/25	Canada	Cushing disease			11,	11/31
Razak AA 2013 (20)	2008.1	Retrospective	40/40	N	Pituitary adenomas	47.4	49.3	19/21	22/18
Starke RM 2013 (21)	2004.8-2009.10	Retrospective	72/41	NSA	Acromegaly	49.2 (14.9)	47.5 (14.2)	40/32	20/21
Cheng RX 2011 (22)	2003.7–2009.7	Retrospective	68/59	China	Functioning pituitary adenomas	37.2	33.8	51,	51/76
Massimi L 2011 (23)	2000–2005	Retrospective	17/14	Italy	Pituitary adenomas	10.2	11.4	14,	14/17
Messerer M 2011 (24)	2006–2009	Retrospective	82/82	France	Nonfunctioning pituitary adenomas	57	56.9	98	98/66
D'Haens J 2009 (25)	1995.2–2007.1	Retrospective	60/60	Belgium	Functioning pituitary adenomas				
Choe JH 2008 (26)	1997–2004	Retrospective	12/11	Korea	Functioning pituitary adenomas	47±12	48±10	7/5	9/2
Hindins TS 2008 (27)		Dotrochootive	10/00	л II	Dituitory odonomos	24.0	50 0	0 E	05/03

	te circo de la C		Sample size			Ąć	Age	Sex	Xé
study	stuay perioa	stuay aesign	(end/mic)	Country	Ulsease	Endoscopic	Endoscopic Microscopic	Endoscopic	Endoscopic Microscopic
O'Malley BW 2008 (28) 2003.7-2008.5	2003.7-2008.5	Retrospective	25/25	NSA	Pituitary adenomas	47.9 (18–73)	50.8 (23–78)	15/10	16/9
Neal JG 2007 (29)	1999–2004	Retrospective	21/15	NSA	Pituitary adenomas	51	39	9/12	5/10
Cappabianca P 1999 (30)	1997.1–1997.6	Retrospective	10/20	NSA	Pituitary adenomas	33–67	20-68	6/4	11/9
Koren I 1999 (31)	1993.1–1997.6	Retrospective	20/20	Israel	Pituitary adenomas				
Sheehan MT 1999 (32) 1995.1–1997.10	1995.1–1997.10	Retrospective	26/44	NSA	Nonfunctioning pituitary adenomas	59.2 (15.1)	57.8 (14.9)	18/8	31/13
White DR 2004 (33)	1996–2002	Retrospective	50/50	NSA	Pituitary adenomas	41.1	43.5	24/26	33/17
Casler JD 2005 (34)	1996.11–2003.7	Retrospective	15/15	NSA	Pituitary adenomas	41.6	50.66	6/9	10/5




Figure 1 Flow diagram showing the study selection process.

group and the microscopic surgery group (RR =1.73, 95% CI: 0.80–3.76, P=0.17, *Figure 7*).

Meningitis

Ten studies reported the incidence of postoperative meningitis in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. No significant difference was found in the incidence of meningitis between the endoscopic surgery group and the microscopic surgery group (RR =1.20, 95% CI: 0.68–2.14, P=0.53, *Figure 8*).

Hypothyroidism

Eight studies reported the incidence of postoperative hypopituitarism in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. The results showed no significant difference in the incidence of hypopituitarism between the endoscopic surgery group and the microscopic surgery group (RR =0.80, 95% CI: 0.55–1.18, P=0.26, *Figure 9*).

Visual improvement

Five studies analyzed the visual improvement rate in patients with pituitary tumors who underwent endoscopic transsphenoidal resection and microscopic transsphenoidal

Chen et al. Scopic surgery for pituitary adenoma

studies
included
it of the
assessmen
Quality
Table 2

© Gland Surgery. All rights reserved.

		Selection			Comparability		Exposure	
Study	Adequate case definition	Representativeness	Selection of controls	Definition of controls	Comparability of cases and controls: most important factor	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-response rate
Bora SK 2020	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Pablo A 2019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Agam MS 2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Akbari H 2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Wang AC 2018	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Eseonu CI 2017	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Levi V 2017	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fathalla H 2015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Karppinen A 2015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lenzi 2015	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dallapiazza R 2014	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Halvorsen H 2014	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sarkar S 2014	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Alahmadi H 2013	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Razak AA 2013	Yes	No	Yes	Yes	Yes	No	Yes	Yes
Starke RM 2013	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes
Cheng RX 2011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Massimi L 2011	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Messerer M 2011	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
D'Haens J 2009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Choe JH 2008	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Higgins TS 2008	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
O'Malley BW 2008	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Neal JG 2007	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Casler JD 2005	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
White DR 2004	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Cappabianca P 1999) Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Koren I 1999	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes
Sheehan MT 1999	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes

2167

	ETS		MTS			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% Cl
Akbari H 2018	13	16	3	19	1.3%	5.15 [1.77, 14.92]	
Cappabianca P 1999	9	10	14	20	7.4%	1.29 [0.90, 1.83]	+
Casler JD 2005	10	15	12	15	5.7%	0.83 [0.54, 1.29]	
Choe JH 2008	10	12	8	11	5.6%	1.15 [0.74, 1.78]	
Dallapiazza R 2014	54	56	40	43	15.2%	1.04 [0.94, 1.14]	•
Fathalla H 2015	25	41	8	19	3.8%	1.45 [0.81, 2.59]	
Karppinen A 2015	23	41	64	144	8.0%	1.26 [0.91, 1.75]	
Massimi L 2011	10	13	10	14	5.6%	1.08 [0.69, 1.68]	
Messerer M 2011	61	82	42	82	10.3%	1.45 [1.14, 1.86]	-
Neal JG 2007	15	21	10	15	5.5%	1.07 [0.68, 1.68]	+-
O'Malley BW 2008	14	21	17	22	6.8%	0.86 [0.59, 1.26]	-
Pablo A 2019	84	140	183	259	13.3%	0.85 [0.73, 0.99]	-
Sheehan MT 1999	7	16	15	36	3.0%	1.05 [0.53, 2.07]	
Wang AC 2018	75	117	21	37	8.4%	1.13 [0.83, 1.54]	+-
Total (95% CI)		601		736	100.0%	1.11 [0.97, 1.26]	♦
Total events	410		447				
Heterogeneity: Tau ² = 0).03; Chi² :	= 29.43	3, df = 13 ((P = 0.0	006); l² = 5	6%	
Test for overall effect: Z	z = 1.56 (P	9 = 0.12	2)				0.01 0.1 1 10 100
			,				Favours experimental Favours control

Figure 2 Comparison of gross tumor removal (GTR) between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS		MTS	;		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
Alahmadi H 2013	10	17	16	25	5.9%	0.92 [0.56, 1.51]	
Bora SK 2020	48	54	17	30	10.0%	1.57 [1.13, 2.17]	-
Choe JH 2008	10	12	5	11	2.4%	1.83 [0.91, 3.67]	
Fathalla H 2015	19	42	8	23	4.7%	1.30 [0.68, 2.49]	
O'Malley BW 2008	7	25	8	25	3.7%	0.88 [0.37, 2.05]	
Pablo A 2019	61	81	126	160	38.8%	0.96 [0.82, 1.11]	•
Razak AA 2013	15	16	8	14	3.9%	1.64 [1.02, 2.63]	
Sarkar S 2014	19	66	17	47	9.1%	0.80 [0.47, 1.36]	
Starke RM 2013	51	72	28	41	16.3%	1.04 [0.80, 1.34]	+
Wang AC 2018	22	35	8	14	5.2%	1.10 [0.65, 1.85]	+-
Total (95% CI)		420		390	100.0%	1.08 [0.97, 1.21]	•
Total events	262		241				
Heterogeneity: Chi ² = ²	15.17, df =	9 (P =	0.09); l ²	= 41%			
Test for overall effect:		•				ł	0.01 0.1 1 10 100 Favours experimental Favours control

Figure 3 Comparison of the hormone excess secretion (HES) remission rates between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

resection. The results showed that there was no significant difference in the visual improvement rate between the endoscopic surgery group and the microscopic surgery group (RR =1.01, 95% CI: 0.87–1.17, P=0.89, *Figure 10*).

Vision loss

Seven studies reported the incidence of postoperative visual impairment in patients with pituitary tumors who underwent endoscopic transsphenoidal resection or microscopic transsphenoidal resection. The results revealed no significant difference in the incidence of visual impairment between the endoscopic surgery group and the microscopic surgery group (RR =1.05, 95% CI: 0.56-1.96, P=0.89, *Figure 11*).

Publication bias

The funnel chart showed that no publication bias existed (Figures S1-S10).

	ETS	5	мтя	5		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Agam MS 2018	34	170	164	983	17.3%	1.20 [0.86, 1.67]	
Cappabianca P 1999	4	10	2	20	5.3%	4.00 [0.88, 18.26]	
Cheng RX 2011	17	68	17	59	14.1%	0.87 [0.49, 1.54]	
Koren I 1999	4	20	11	20	9.4%	0.36 [0.14, 0.95]	
Massimi L 2011	4	17	4	14	7.4%	0.82 [0.25, 2.71]	
Pablo A 2019	21	140	68	259	15.9%	0.57 [0.37, 0.89]	
Sheehan MT 1999	7	26	9	44	10.5%	1.32 [0.56, 3.11]	
Wang AC 2018	5	60	1	24	3.2%	2.00 [0.25, 16.24]	
White DR 2004	20	50	45	50	17.0%	0.44 [0.31, 0.63]	
Total (95% CI)		561		1473	100.0%	0.82 [0.54, 1.23]	•
Total events	116		321				
Heterogeneity: Tau ² = (0.22; Chi ²	= 27.51	, df = 8 (I	P = 0.0	006); l² = 7	71%	
Test for overall effect: 2	Z = 0.96 (F	P = 0.34)				0.01 0.1 1 10 100 Favours experimental Favours control

Figure 4 Comparison of the overall complication rates of endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

<mark>Study or Subgroup</mark> Agam MS 2018 Akbari H 2018 Alahmadi H 2013	Events 6 3	<u>Total</u> 170		Total	Weight	M H Eixed 05% C	M-H, Fixed, 95% Cl
Akbari H 2018		170			mongine	M-H, Fixed, 95% C	<u>м-п, гіхеа, 95% Сі</u>
	3		24	983	4.2%	1.45 [0.60, 3.48]	
Vahmadi H 2013		16	2	19	1.1%	1.78 [0.34, 9.38]	<u> </u>
1annau n 2015	2	17	0	25	0.2%	7.22 [0.37, 141.66]	
Casler JD 2005	4	15	3	15	1.8%	1.33 [0.36, 4.97]	
Cheng RX 2011	11	68	8	59	5.1%	1.19 [0.51, 2.77]	
Choe JH 2008	2	12	2	11	1.3%	0.92 [0.15, 5.44]	
D'Haens J 2009	6	60	1	60	0.6%	6.00 [0.74, 48.34]	
Dallapiazza R 2014	37	56	17	43	11.5%	1.67 [1.10, 2.53]	
Eseonu CI 2017	10	275	8	109	6.9%	0.50 [0.20, 1.22]	
Fathalla H 2015	2	42	2	23	1.6%	0.55 [0.08, 3.64]	
Halvorsen H 2014	12	238	12	268	6.8%	1.13 [0.52, 2.46]	
Higgins TS 2008	1	19	1	29	0.5%	1.53 [0.10, 22.96]	
Karppinen A 2015	1	41	5	144	1.3%	0.70 [0.08, 5.85]	
_evi V 2017	8	140	5	81	3.8%	0.93 [0.31, 2.74]	
Massimi L 2011	2	17	2	14	1.3%	0.82 [0.13, 5.12]	
Messerer M 2011	10	82	7	82	4.2%	1.43 [0.57, 3.57]	
Neal JG 2007	2	21	2	15	1.4%	0.71 [0.11, 4.52]	
D'Malley BW 2008	3	25	1	25	0.6%	3.00 [0.33, 26.92]	
Pablo A 2019	3	140	8	259	3.4%	0.69 [0.19, 2.57]	
Razak AA 2013	4	40	6	40	3.6%	0.67 [0.20, 2.18]	
Sarkar S 2014	23	66	19	47	13.3%	0.86 [0.53, 1.39]	
Sheehan MT 1999	3	26	7	44	3.1%	0.73 [0.21, 2.56]	
Starke RM 2013	25	72	13	41	9.9%	1.10 [0.63, 1.90]	- - -
Vang AC 2018	1	60	0	24	0.4%	1.23 [0.05, 29.17]	
White DR 2004	12	50	20	50	12.0%	0.60 [0.33, 1.09]	
Fotal (95% CI)		1768		2510	100.0%	1.06 [0.88, 1.28]	•
Total events	193		175				
Heterogeneity: Chi ² = 2	20.51, df =	: 24 (P	= 0.67); l	² = 0%			
Test for overall effect: 2		`					0.01 0.1 1 10 100 Favours experimental Favours control

Figure 5 Comparison of the incidence of cerebrospinal fluid (CSF) leakage between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS	5	MTS			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Agam MS 2018	8	170	45	983	10.2%	1.03 [0.49, 2.14]	_ + _
Akbari H 2018	5	16	4	19	2.8%	1.48 [0.48, 4.61]	
Alahmadi H 2013	4	17	7	25	4.4%	0.84 [0.29, 2.43]	
Casler JD 2005	3	15	2	15	1.5%	1.50 [0.29, 7.73]	
Cheng RX 2011	2	68	3	59	2.5%	0.58 [0.10, 3.34]	
Choe JH 2008	1	12	1	11	0.8%	0.92 [0.06, 12.95]	
Dallapiazza R 2014	10	56	7	43	6.1%	1.10 [0.45, 2.65]	
Eseonu CI 2017	2	275	1	109	1.1%	0.79 [0.07, 8.65]	
Fathalla H 2015	9	41	12	23	11.9%	0.42 [0.21, 0.84]	
Higgins TS 2008	5	19	7	29	4.3%	1.09 [0.40, 2.94]	
Karppinen A 2015	2	41	11	144	3.8%	0.64 [0.15, 2.77]	
Levi V 2017	3	140	3	81	2.9%	0.58 [0.12, 2.80]	
Messerer M 2011	7	82	8	82	6.2%	0.88 [0.33, 2.30]	
Neal JG 2007	1	21	5	15	4.5%	0.14 [0.02, 1.10]	
O'Malley BW 2008	1	25	4	25	3.1%	0.25 [0.03, 2.08]	
Pablo A 2019	9	140	27	259	14.6%	0.62 [0.30, 1.27]	
Razak AA 2013	4	40	11	40	8.5%	0.36 [0.13, 1.05]	
Sarkar S 2014	6	66	2	47	1.8%	2.14 [0.45, 10.13]	
Sheehan MT 1999	1	26	1	44	0.6%	1.69 [0.11, 25.92]	
White DR 2004	11	50	11	50	8.5%	1.00 [0.48, 2.09]	
Total (95% CI)		1320		2103	100.0%	0.76 [0.60, 0.97]	•
Total events	94		172				
Heterogeneity: Chi ² =	15.35, df =	= 19 (P	= 0.70); l²	² = 0%			
Test for overall effect:	Z = 2.18 (I	P = 0.0	3)				0.01 0.1 1 10 100 Favours experimental Favours control

Figure 6 Comparison of the incidence of diabetes insipidus (DI) between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS	;	мтя	5		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% (M-H, Fix	ed, 95% Cl	
Agam MS 2018	5	170	8	983	29.0%	3.61 [1.20, 10.92]]			
Fathalla H 2015	1	42	1	23	15.9%	0.55 [0.04, 8.35	-] -		<u> </u>	
Koren I 1999	0	20	2	20	30.7%	0.20 [0.01, 3.92	j —	-	+	
Starke RM 2013	4	72	1	41	15.7%	2.28 [0.26, 19.70]]		+ •	-
Wang AC 2018	2	60	0	24	8.7%	2.05 [0.10, 41.18]]		 •	
Total (95% CI)		364		1091	100.0%	1.73 [0.80, 3.76]	1			
Total events	12		12							
Heterogeneity: Chi ² =	4.48, df =	4 (P = 0	0.34); l² =	11%						100
Test for overall effect:	Z = 1.39 (P = 0.1	7)				0.01 Favours	0.1 experimental	1 10 Favours cor	100 Itrol

Figure 7 Comparison of the incidence of epistaxis between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

Discussion

At present, transsphenoidal tumor resection employing a neuroendoscopic or microscopic approach is the standard surgical treatment for pituitary tumors. However, the short-term effects of these two surgical methods are still controversial. In recent years, an increasing number of high-quality clinical studies have been conducted on the application of these two surgical methods in the treatment of pituitary tumors. However, the latest result of evidencebased medicine research has not been updated in time.

This meta-analysis of 29 case-control studies compared the efficacy and safety of neuroendoscopic and microscopic transsphenoidal resection for the treatment of pituitary tumors. The results showed that in terms of clinical efficacy,

	ETS		мтя	5		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
Agam MS 2018	2	170	10	983	14.1%	1.16 [0.26, 5.23]	
Akbari H 2018	2	16	1	19	4.4%	2.38 [0.24, 23.84]	
Choe JH 2008	0	12	1	11	7.5%	0.31 [0.01, 6.85]	
Dallapiazza R 2014	8	56	2	43	10.8%	3.07 [0.69, 13.73]	
Eseonu CI 2017	2	275	0	109	3.4%	1.99 [0.10, 41.17]	
Messerer M 2011	3	82	4	82	19.2%	0.75 [0.17, 3.25]	
Pablo A 2019	3	140	7	259	23.6%	0.79 [0.21, 3.02]	
Sarkar S 2014	1	66	2	47	11.2%	0.36 [0.03, 3.81]	
Wang AC 2018	2	60	0	24	3.4%	2.05 [0.10, 41.18]	
White DR 2004	1	50	0	50	2.4%	3.00 [0.13, 71.92]	
Total (95% CI)		927		1627	100.0%	1.20 [0.68, 2.14]	•
Total events	24		27				
Heterogeneity: Chi ² = 4	4.92, df = :	9 (P = 0	0.84); l² =	0%			
Test for overall effect:		•					0.01 0.1 1 10 100 Favours experimental Favours control

Figure 8 Comparison of the incidence of meningitis between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS	;	MTS	6		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	;	M-H, Fix	ed, 95% Cl	
Agam MS 2018	6	170	35	983	20.8%	0.99 [0.42, 2.32]			┿ ──	
Akbari H 2018	5	16	7	19	12.9%	0.85 [0.33, 2.16]			-	
Alahmadi H 2013	1	17	3	25	4.9%	0.49 [0.06, 4.33]			<u> </u>	
Choe JH 2008	1	12	3	11	6.3%	0.31 [0.04, 2.52]	-	-	+	
Eseonu CI 2017	9	275	7	109	20.2%	0.51 [0.19, 1.33]			+	
Fathalla H 2015	5	42	1	23	2.6%	2.74 [0.34, 22.05]				
Massimi L 2011	2	17	4	14	8.8%	0.41 [0.09, 1.93]			+-	
Sarkar S 2014	14	66	10	47	23.5%	1.00 [0.49, 2.05]			•	
Total (95% CI)		615		1231	100.0%	0.80 [0.55, 1.18]				
Total events	43		70							
Heterogeneity: Chi ² = 4	1.50, df = [•]	7 (P = 0).72); l² =	0%			0.01	0.1		100
Test for overall effect: 2	Z = 1.12 (P = 0.2	6)					experimental	1 10 Favours contro	

Figure 9 Comparison of the incidence of hypothyroidism between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS	;	MTS	5		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	N M	-H, Fixed, 95%	6 CI	
Cheng RX 2011	7	7	6	8	4.4%	1.30 [0.83, 2.02]		+		
D'Haens J 2009	4	4	0	1	0.5%	3.60 [0.32, 40.41]				—
Eseonu CI 2017	100	275	42	109	43.2%	0.94 [0.71, 1.25]		+		
Karppinen A 2015	31	33	76	93	28.6%	1.15 [1.01, 1.31]		•		
Messerer M 2011	29	57	31	52	23.3%	0.85 [0.61, 1.20]				
Total (95% CI)		376		263	100.0%	1.01 [0.87, 1.17]		•		
Total events	171		155							
Heterogeneity: Chi ² =	7.26, df =	4 (P = (0.12); I² =	45%						
Test for overall effect:	Z = 0.14 (P = 0.8	9)			0.01 0.1 Favours experin	nental Favor	10 urs contro	100 I	

Figure 10 Comparison of the visual improvement rates of endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

	ETS	;	MTS	;		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
Agam MS 2018	0	170	7	983	12.3%	0.38 [0.02, 6.69]	
Akbari H 2018	5	16	5	19	25.2%	1.19 [0.42, 3.38]	
Choe JH 2008	0	12	0	11		Not estimable	
Dallapiazza R 2014	2	56	0	43	3.1%	3.86 [0.19, 78.36]	
Eseonu CI 2017	15	275	4	109	31.6%	1.49 [0.50, 4.38]	
Levi V 2017	2	140	2	81	14.0%	0.58 [0.08, 4.03]	
White DR 2004	0	50	2	50	13.8%	0.20 [0.01, 4.06]	• • •
Total (95% CI)		719		1296	100.0%	1.05 [0.56, 1.96]	+
Total events	24		20				
Heterogeneity: Chi ² = 3	3.18, df =	5 (P = (
Test for overall effect:	Z = 0.14 (P = 0.8		0.01 0.1 1 10 100 Favours experimental Favours control			

Figure 11 Comparison of the incidence of vision loss between endoscopic transsphenoidal surgery (ETS) and microscopic transsphenoidal surgery (MTS).

there was no statistically significant difference in the rates of tumor total resection, hormone over-secretion, or visual improvement between the two surgical methods. In terms of safety, neuroendoscopic transsphenoidal surgery could significantly reduce the postoperative incidence of DI, although total complications, CSF leakage, epistaxis, meningitis, and other complications did not differ significantly between the two methods.

Although the resection rates of the two techniques did not show a significant difference, the ease of operation of the endoscope is an advantage in more complex operations. The use of an angled endoscope and its large range of movement can facilitate the removal of tumors that cannot be reached using the traditional transsphenoidal approach. Second, due to its flexibility, the endoscope can be inserted into the resected tumor cavity at the end of the operation to look for residual tumor, which makes intraoperative magnetic resonance imaging unnecessary. For large tumors that may be accompanied by CSF leakage, the use of an endoscope offers the advantage of a panoramic field of view.

The postoperative recovery of vision in patients with pituitary tumors is affected by factors including the age of onset, the preoperative degree of visual field defect, tumor size, and other factors. Following surgery, the vision of most patients is improved to varying degrees. However, there is no evidence that the choice of surgical method can affect postoperative recovery of vision, and our results cannot prove this.

Postoperative DI is transient in most cases, and few patients develop permanent DI. The occurrence of DI is affected by the precision of the surgeon. The neuroendoscopic transsphenoidal approach can reduce the incidence of DI, which may be related to the fact that neuroendoscopy can provide a better operative field of view.

CSF leakage is a common postoperative complication. The incidence of CSF leakage for neuroendoscopy and microscopy is 5-7% and 6.34-8%, respectively. Neuroendoscopy allows the diseased tissue and its surrounding structures, as well as the blind corners of the visual field that cannot be seen under a microscope, to be clearly observed. Therefore, the incidence of postoperative CSF leakage with a neuroendoscope is lower than that with a microscope. However, our results showed no significant difference in the incidence of postoperative CSF fistula between the neuroendoscopic and microscopic surgery groups. There may be three reasons for this: First, the studies we included were all case-control studies with a relatively low level of evidence. Secondly, the number of patients was insufficient. Thirdly, the incidence of postoperative CSF leakage was not significantly affected by the surgical method adopted. This result still needs to be verified by more high-quality large-sample randomized controlled studies.

This study has certain limitations. First, only retrospective case-control studies were included, and most of them did not describe the method for evaluating the tumor total resection rate in detail. The studies also included different types of pituitary tumors, and it was impossible to determine whether postoperative results are correlated with the type of pituitary tumor.

Conclusions

The results of this meta-analysis suggest that neuroendoscopic

transsphenoidal surgery does not significantly increase the tumor total resection rate or the remission rate of excessive hormone secretion. However, this surgical method was found to significantly reduce the incidence of postoperative DI without increasing the incidence of other complications.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at http://dx.doi. org/10.21037/gs-20-851

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi. org/10.21037/gs-20-851). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- 1. Yang C, Zhang J, Li J, et al. The role of multimodal navigation in endoscopic endonasal surgery for giant pituitary adenomas. Gland Surg 2019;8:663-73.
- Wang AJ, Zaidi HA, Laws ED Jr. History of endonasal skull base surgery. J Neurosurg Sci 2016;60:441-53.
- 3. Jankowski R, Auque J, Simon C, et al. Endoscopic pituitary tumor surgery. Laryngoscope 1992;102:198-202.
- 4. Laufer I, Anand VK, Schwartz TH. Endoscopic, endonasal extended transsphenoidal, transplanum transtuberculum approach for resection of suprasellar lesions. J Neurosurg

2007;106:400-6.

- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603-5.
- Bora SK, Suri A, Khadgawat R, et al. Management of Cushing's Disease: Changing Trend from Microscopic to Endoscopic Surgery. World Neurosurg 2020;134:e46-e54.
- Pablo A, Sofia B, Maximiliano T, et al. Endoscopic versus Microscopic Pituitary Adenoma Surgery: A Single-center Study. Neurol India 2019;67:1015-21.
- Agam MS, Wedemeyer MA, Wrobel B, et al. Complications associated with microscopic and endoscopic transsphenoidal pituitary surgery: experience of 1153 consecutive cases treated at a single tertiary care pituitary center. J Neurosurg 2018. [Epub ahead of print]. doi: 10.3171/2017.12.
- 9. Akbari H, Malek M, Ghorbani M, et al. Clinical outcomes of endoscopic versus microscopic trans-sphenoidal surgery for large pituitary adenoma. Br J Neurosurg 2018;32:206-9.
- Wang AC, Shah AH, Sidani C, et al. Volumetry in the Assessment of Pituitary Adenoma Resection: Endoscopy versus Microscopy. J Neurol Surg B Skull Base 2018;79:538-44.
- Eseonu CI, ReFaey K, Rincon-Torroella J, et al. Endoscopic Versus Microscopic Transsphenoidal Approach for Pituitary Adenomas: Comparison of Outcomes During the Transition of Methods of a Single Surgeon. World Neurosurg 2017;97:317-25.
- Levi V, Bertani GA, Guastella C, et al. Microscopic versus endoscopic transsphenoidal surgery for pituitary adenoma: analysis of surgical safety in 221 consecutive patients. Clin Otolaryngol 2017;42:466-9.
- Fathalla H, Cusimano MD, Di Ieva A, et al. Endoscopic versus microscopic approach for surgical treatment of acromegaly. Neurosurg Rev 2015;38:541-8; discussion 548-9.
- Karppinen A, Kivipelto L, Vehkavaara S, et al. Transition From Microscopic to Endoscopic Transsphenoidal Surgery for Nonfunctional Pituitary Adenomas. World Neurosurg 2015;84:48-57.
- Lenzi J, Lapadula G, D'amico T, et al, Gargiulo P. Evaluation of trans-sphenoidal surgery in pituitary GHsecreting micro- and macroadenomas: a comparison between microsurgical and endoscopic approach. J Neurosurg Sci 2015;59:11-8.
- Dallapiazza R, Bond AE, Grober Y, et al. Retrospective analysis of a concurrent series of microscopic versus endoscopic transsphenoidal surgeries for Knosp Grades

Chen et al. Scopic surgery for pituitary adenoma

0-2 nonfunctioning pituitary macroadenomas at a single institution. J Neurosurg 2014;121:511-7.

- Halvorsen H, Ramm-Pettersen J, Josefsen R, et al. Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir (Wien) 2014;156:441-9.
- Sarkar S, Rajaratnam S, Chacko G, et al. Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly. Clin Neurol Neurosurg 2014;126:190-5.
- Alahmadi H, Cusimano MD, Woo K, et al. Impact of technique on cushing disease outcome using strict remission criteria. Can J Neurol Sci 2013;40:334-41.
- Razak AA, Horridge M, Connolly DJ, et al. Comparison of endoscopic and microscopic trans-sphenoidal pituitary surgery: early results in a single centre. Br J Neurosurg 2013;27:40-3.
- 21. Starke RM, Raper DM, Payne SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 2013;98:3190-8.
- 22. Cheng RX, Tian HL, Gao WW, et al. A comparison between endoscopic trans-sphenoidal surgery and traditional trans-sphenoidal microsurgery for functioning pituitary adenomas. J Int Med Res 2011;39:1985-93.
- Massimi L, Rigante M, D'Angelo L, et al. Quality of postoperative course in children: endoscopic endonasal surgery versus sublabial microsurgery. Acta Neurochir (Wien) 2011;153:843-9.
- 24. Messerer M, De Battista JC, Raverot G, et al. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. Neurosurg Focus 2011;30:E11.
- 25. D'Haens J, Van Rompaey K, Stadnik T, et al. Fully endoscopic transsphenoidal surgery for functioning

Cite this article as: Chen X, Huang W, Li H, Huan Y, Mai G, Chen L, Huang H, Xu H. Comparison of outcomes between endoscopic and microscopic transsphenoidal surgery for the treatment of pituitary adenoma: a meta-analysis. Gland Surg 2020;9(6):2162-2174. doi: 10.21037/gs-20-851


pituitary adenomas: a retrospective comparison with traditional transsphenoidal microsurgery in the same institution. Surg Neurol 2009;72:336-40.

- Choe JH, Lee KS, Jeun SS, et al. Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas. J Korean Neurosurg Soc 2008;44:151-5.
- 27. Higgins TS, Courtemanche C, Karakla D, et al. Analysis of transnasal endoscopic versus transseptal microscopic approach for excision of pituitary tumors. Am J Rhinol 2008;22:649-52.
- O'Malley BW Jr, Grady MS, Gabel BC, et al. Comparison of endoscopic and microscopic removal of pituitary adenomas: single-surgeon experience and the learning curve. Neurosurg Focus 2008;25:E10.
- Neal JG, Patel SJ, Kulbersh JS, et al. Comparison of techniques for transsphenoidal pituitary surgery. Am J Rhinol 2007;21:203-6.
- Cappabianca P, Alfieri A, Colao A, et al. Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg 1999;9:109-17.
- Koren I, Hadar T, Rappaport ZH, et al. Endoscopic transnasal transsphenoidal microsurgery versus the sublabial approach for the treatment of pituitary tumors: endonasal complications. Laryngoscope 1999;109:1838-40.
- 32. Sheehan MT, Atkinson JL, Kasperbauer JL, et al. Preliminary comparison of the endoscopic transnasal vs the sublabial transseptal approach for clinically nonfunctioning pituitary macroadenomas. Mayo Clin Proc 1999;74:661-70.
- White DR, Sonnenburg RE, Ewend MG, et al. Safety of minimally invasive pituitary surgery (MIPS) compared with a traditional approach. Laryngoscope 2004;114:1945-8.
- 34. Casler JD, Doolittle AM, Mair EA. Endoscopic surgery of the anterior skull base. Laryngoscope 2005;115:16-24.

(English Language Editor: J. Reynolds)

2174

Supplementary








Figure S2 DI Funnel plot.





Figure S3 Epistaxis Funnel plot.








Figure S5 HES remission Funnel plot.




Figure S6 Hypopituitarism Funnel plot.




Figure S7 Meningtis Funnel plot.




Figure S8 Overall complication Funnel plot.




Figure S9 Visual improvement Funnel plot.




Figure S10 Worsened vision Funnel plot.